Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

207 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.
Montemurro M, Gelderblom H, Bitz U, Schütte J, Blay JY, Joensuu H, Trent J, Bauer S, Rutkowski P, Duffaud F, Pink D. Montemurro M, et al. Among authors: pink d. Eur J Cancer. 2013 Mar;49(5):1027-31. doi: 10.1016/j.ejca.2012.10.009. Epub 2012 Nov 6. Eur J Cancer. 2013. PMID: 23140824
Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas.
Nielsen OS, Reichardt P, Christensen TB, Pink D, Daugaard S, Hermans C, Marreaud S, van Glabbeke M, Blay J, Judson I. Nielsen OS, et al. Among authors: pink d. Eur J Cancer. 2006 Sep;42(14):2303-9. doi: 10.1016/j.ejca.2006.04.011. Epub 2006 Aug 7. Eur J Cancer. 2006. PMID: 16891112 Clinical Trial.
Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group.
Reichardt P, Nielsen OS, Bauer S, Hartmann JT, Schöffski P, Christensen TB, Pink D, Daugaard S, Marreaud S, Van Glabbeke M, Blay JY; EORTC Soft Tissue and Bone Sarcoma Group. Reichardt P, et al. Among authors: pink d. Eur J Cancer. 2007 Apr;43(6):1017-22. doi: 10.1016/j.ejca.2007.01.014. Epub 2007 Mar 1. Eur J Cancer. 2007. PMID: 17336054 Clinical Trial.
A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.
Demetri GD, Casali PG, Blay JY, von Mehren M, Morgan JA, Bertulli R, Ray-Coquard I, Cassier P, Davey M, Borghaei H, Pink D, Debiec-Rychter M, Cheung W, Bailey SM, Veronese ML, Reichardt A, Fumagalli E, Reichardt P. Demetri GD, et al. Among authors: pink d. Clin Cancer Res. 2009 Sep 15;15(18):5910-6. doi: 10.1158/1078-0432.CCR-09-0542. Epub 2009 Sep 1. Clin Cancer Res. 2009. PMID: 19723647 Free PMC article. Clinical Trial.
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegård T, Reichardt P. Joensuu H, et al. Among authors: pink d. JAMA. 2012 Mar 28;307(12):1265-72. doi: 10.1001/jama.2012.347. JAMA. 2012. PMID: 22453568 Clinical Trial.
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors.
Bauer S, Hilger RA, Mühlenberg T, Grabellus F, Nagarajah J, Hoiczyk M, Reichardt A, Ahrens M, Reichardt P, Grunewald S, Scheulen ME, Pustowka A, Bock E, Schuler M, Pink D. Bauer S, et al. Among authors: pink d. Br J Cancer. 2014 Mar 4;110(5):1155-62. doi: 10.1038/bjc.2013.826. Epub 2014 Jan 16. Br J Cancer. 2014. PMID: 24434430 Free PMC article. Clinical Trial.
Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.
Joensuu H, Eriksson M, Hall KS, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Ballman KV, Leinonen M, DeMatteo RP, Reichardt P. Joensuu H, et al. Among authors: pink d. Cancer. 2014 Aug 1;120(15):2325-33. doi: 10.1002/cncr.28669. Epub 2014 Apr 15. Cancer. 2014. PMID: 24737415 Free PMC article. Clinical Trial.
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.
Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, Ramadori G, Hohenberger P, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Nilsson B, Sihto H, Bono P, Kallio R, Junnila J, Alvegård T, Reichardt P. Joensuu H, et al. Among authors: pink d. J Clin Oncol. 2016 Jan 20;34(3):244-50. doi: 10.1200/JCO.2015.62.9170. Epub 2015 Nov 2. J Clin Oncol. 2016. PMID: 26527782 Clinical Trial.
207 results